Chipping Norton

Researchers are evaluating IMVT-1402 in a global, randomized, double-blind, placebo-controlled Phase 2b study for adults with Graves disease GD who remain hyperthyroid despite antithyroid drug ATD treatment. The study aims to assess the efficacy, safety, and tolerability of IMVT-1402 in this population. Participants will receive one of two doses of IMVT-1402 or a placebo for 26 weeks. The study includes two experimental groups with different doses of IMVT-1402 and a placebo comparator group. Treatments are given over the same 26-week period to evaluate their effects. During the study, participants will be monitored to see if they become euthyroid and are able to stop ATD by Week 26. Researchers will measure thyroid hormone levels such as triiodothyronine T3 and free thyroxine FT4 at various time points, including Weeks 2, 4, and 26. Safety and tolerability will also be assessed throughout the trial, which is expected to complete in May 2027.

Researchers are studying advanced pelvic cancers, which are rare and often require complex treatment involving radiotherapy, chemotherapy, and surgery. Surgery typically involves removing multiple pelvic organs and surrounding tissues, which can lead to complications affecting recovery and quality of life. This study aims to investigate the frequency of these complications, quality of life, and related costs following different reconstruction techniques to help improve decision-making for patients and doctors. This observational study has three parts maintaining a database of patients undergoing colorectal surgery, conducting a national prospective cohort study to assess morbidity, quality of life, and healthcare resource use, and a qualitative study using interviews to explore patient experiences after surgery. Patients undergoing surgeries like abdominoperineal excision or pelvic exenteration will be followed, with reconstruction methods chosen by the surgeon. Data such as surgery details, complications, and resource use will be collected and analyzed. Participants will complete quality of life and financial impact questionnaires at baseline, 3, 6, and 12 months after surgery, either by telephone or email. Clinical data, imaging, and hospital resource use will also be recorded. The qualitative study will involve interviews with selected patients at 3 and 12 months post-surgery to deepen understanding of recovery and long-term outcomes. The study will analyze these data to evaluate the impact of different reconstruction methods on patient health and healthcare costs over time.